2025 Q4 -tulosraportti
Vain PDF
76 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 52 | - | - | ||
| 207 | - | - | ||
| 472 | - | - | ||
| 128 | - | - | ||
| 1 669 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 206 507 | 206 507 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 206 507 | 206 507 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 26.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·13 t sitten · MuokattuEven though I have otherwise blocked that conspiracy guy who keeps babbling that it's all a scam and manipulated - he still shows up in my feed, and only disappears when I click. I don't think many people read his posts, but I would like to point out that if he knew how real professionals (I am NOT one - but I do know how they calculate) value biotech, he would clearly see that the price is exactly where it should be. It's pure statistics, probability, and mathematics. See post from 5/5 just below. With various models, one arrives at risk-adjusted Bear: 6-8 / risk-adjusted base: 12-18 / risk-adjusted bull: 18-25. Industrial buyers will probably be between 20 and 25+, as they calculate differently, but pension funds, private equity funds, investment bankers and similar who just buy and sell listed shares, will probably place themselves in the lower bear in the Saniona case due to the very high risk in the pipeline - even though there are a total of 5 shots on goal and a library. The price is 100% rational and fully justified. When progress is made, the risk adjustment will need to be adapted and new price levels will become relevant. CLEARLY the potential is great - and the greater the risk one is willing to take (low risk adjustment) the greater the potential gain also - and that's how it should be - high risk/high upside - low risk/lower upside. Saniona is high risk/high upside if you buy today.- ·5.5. · Muokattu😊 – I've had fun with some statistics together with 2 different AI models to find probabilities for all outcomes of the 5 main projects (Acadia, Jazz + 3 inhouse), so one is nicely free from having emotions involved in the game. Individual LoA’s per asset have been used – partly a "std" source, which apparently should be "Clinical Development Succes Rates and Contribution Factors 2011-2020" from "Biotechnology Innovation Organization" – and partly Redeye’s LoA. I then asked for a statistical probability for all outcomes between 0/5 and 5/0 (When the market/fails). Reportedly, it should involve a "Bernoulli Trial" and a "Poisson-binomial model" :-) - the former I have never heard of, the models I can vaguely recall from the happy and carefree student days at the Business School some decades ago :-) Then I get approximately these outcomes (Redeye / "industry standard"): 0/5: 51,9 / 68,9 1/4: 34,8 / 27,4 2/3: 10,9 / 3,5 3/2: 2,0 / 0,2 4/1: 0,2 / 0,005 5/5: 0,01 / 0,0001 Fun little experiment 😊 I went a bit further, but it became a bit more extensive - something about whether there could be a correlation between the different assets, so if 1 fails, it might have something to do with mechanisms of action and such - and also weighted whether it was a partner or not - but it is fun :-)
·6.5.Saniona can indeed earn a lot of money without requiring the products to reach the market (e.g., via partnership), and Saniona can be acquired for large billion amounts WITHOUT any of the projects having reached the market - but e.g. if "just" 2 of their 3 main projects reach phase 2. And what would be the probability of that? That's probably more relevant than painting the devil on the wall :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
76 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 t sitten · MuokattuEven though I have otherwise blocked that conspiracy guy who keeps babbling that it's all a scam and manipulated - he still shows up in my feed, and only disappears when I click. I don't think many people read his posts, but I would like to point out that if he knew how real professionals (I am NOT one - but I do know how they calculate) value biotech, he would clearly see that the price is exactly where it should be. It's pure statistics, probability, and mathematics. See post from 5/5 just below. With various models, one arrives at risk-adjusted Bear: 6-8 / risk-adjusted base: 12-18 / risk-adjusted bull: 18-25. Industrial buyers will probably be between 20 and 25+, as they calculate differently, but pension funds, private equity funds, investment bankers and similar who just buy and sell listed shares, will probably place themselves in the lower bear in the Saniona case due to the very high risk in the pipeline - even though there are a total of 5 shots on goal and a library. The price is 100% rational and fully justified. When progress is made, the risk adjustment will need to be adapted and new price levels will become relevant. CLEARLY the potential is great - and the greater the risk one is willing to take (low risk adjustment) the greater the potential gain also - and that's how it should be - high risk/high upside - low risk/lower upside. Saniona is high risk/high upside if you buy today.
- ·5.5. · Muokattu😊 – I've had fun with some statistics together with 2 different AI models to find probabilities for all outcomes of the 5 main projects (Acadia, Jazz + 3 inhouse), so one is nicely free from having emotions involved in the game. Individual LoA’s per asset have been used – partly a "std" source, which apparently should be "Clinical Development Succes Rates and Contribution Factors 2011-2020" from "Biotechnology Innovation Organization" – and partly Redeye’s LoA. I then asked for a statistical probability for all outcomes between 0/5 and 5/0 (When the market/fails). Reportedly, it should involve a "Bernoulli Trial" and a "Poisson-binomial model" :-) - the former I have never heard of, the models I can vaguely recall from the happy and carefree student days at the Business School some decades ago :-) Then I get approximately these outcomes (Redeye / "industry standard"): 0/5: 51,9 / 68,9 1/4: 34,8 / 27,4 2/3: 10,9 / 3,5 3/2: 2,0 / 0,2 4/1: 0,2 / 0,005 5/5: 0,01 / 0,0001 Fun little experiment 😊 I went a bit further, but it became a bit more extensive - something about whether there could be a correlation between the different assets, so if 1 fails, it might have something to do with mechanisms of action and such - and also weighted whether it was a partner or not - but it is fun :-)·6.5.Saniona can indeed earn a lot of money without requiring the products to reach the market (e.g., via partnership), and Saniona can be acquired for large billion amounts WITHOUT any of the projects having reached the market - but e.g. if "just" 2 of their 3 main projects reach phase 2. And what would be the probability of that? That's probably more relevant than painting the devil on the wall :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 52 | - | - | ||
| 207 | - | - | ||
| 472 | - | - | ||
| 128 | - | - | ||
| 1 669 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 206 507 | 206 507 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 206 507 | 206 507 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 26.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
76 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 26.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 t sitten · MuokattuEven though I have otherwise blocked that conspiracy guy who keeps babbling that it's all a scam and manipulated - he still shows up in my feed, and only disappears when I click. I don't think many people read his posts, but I would like to point out that if he knew how real professionals (I am NOT one - but I do know how they calculate) value biotech, he would clearly see that the price is exactly where it should be. It's pure statistics, probability, and mathematics. See post from 5/5 just below. With various models, one arrives at risk-adjusted Bear: 6-8 / risk-adjusted base: 12-18 / risk-adjusted bull: 18-25. Industrial buyers will probably be between 20 and 25+, as they calculate differently, but pension funds, private equity funds, investment bankers and similar who just buy and sell listed shares, will probably place themselves in the lower bear in the Saniona case due to the very high risk in the pipeline - even though there are a total of 5 shots on goal and a library. The price is 100% rational and fully justified. When progress is made, the risk adjustment will need to be adapted and new price levels will become relevant. CLEARLY the potential is great - and the greater the risk one is willing to take (low risk adjustment) the greater the potential gain also - and that's how it should be - high risk/high upside - low risk/lower upside. Saniona is high risk/high upside if you buy today.
- ·5.5. · Muokattu😊 – I've had fun with some statistics together with 2 different AI models to find probabilities for all outcomes of the 5 main projects (Acadia, Jazz + 3 inhouse), so one is nicely free from having emotions involved in the game. Individual LoA’s per asset have been used – partly a "std" source, which apparently should be "Clinical Development Succes Rates and Contribution Factors 2011-2020" from "Biotechnology Innovation Organization" – and partly Redeye’s LoA. I then asked for a statistical probability for all outcomes between 0/5 and 5/0 (When the market/fails). Reportedly, it should involve a "Bernoulli Trial" and a "Poisson-binomial model" :-) - the former I have never heard of, the models I can vaguely recall from the happy and carefree student days at the Business School some decades ago :-) Then I get approximately these outcomes (Redeye / "industry standard"): 0/5: 51,9 / 68,9 1/4: 34,8 / 27,4 2/3: 10,9 / 3,5 3/2: 2,0 / 0,2 4/1: 0,2 / 0,005 5/5: 0,01 / 0,0001 Fun little experiment 😊 I went a bit further, but it became a bit more extensive - something about whether there could be a correlation between the different assets, so if 1 fails, it might have something to do with mechanisms of action and such - and also weighted whether it was a partner or not - but it is fun :-)·6.5.Saniona can indeed earn a lot of money without requiring the products to reach the market (e.g., via partnership), and Saniona can be acquired for large billion amounts WITHOUT any of the projects having reached the market - but e.g. if "just" 2 of their 3 main projects reach phase 2. And what would be the probability of that? That's probably more relevant than painting the devil on the wall :)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 52 | - | - | ||
| 207 | - | - | ||
| 472 | - | - | ||
| 128 | - | - | ||
| 1 669 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 206 507 | 206 507 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 206 507 | 206 507 | 0 | 0 |